| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/29/2004 | EP1462148A2 Methods and compositions for the prevention of tolerance to bronchodilators |
| 09/29/2004 | EP1462132A1 Drug releasing elastic band and method |
| 09/29/2004 | EP1462125A2 Adhesive antineoplastic compositions |
| 09/29/2004 | EP1462111A1 Composition for inducing immunotolerance |
| 09/29/2004 | EP1462104A1 Optically pure (-) norcisapride for treating digestive tract disorders |
| 09/29/2004 | EP1462098A1 Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin |
| 09/29/2004 | EP1461614A2 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 09/29/2004 | EP1461610A2 Heme-regulated eukaryotic initiation factor 2 alpha kinase knockout mice and methods for use |
| 09/29/2004 | EP1461450A1 T-bet compositions and methods of use thereof |
| 09/29/2004 | EP1461448A2 Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| 09/29/2004 | EP1461446A2 Lipid-associated molecules |
| 09/29/2004 | EP1461443A2 Carbohydrate-associated proteins |
| 09/29/2004 | EP1461427A2 Methods for targeted expression of therapeutic nucleic acid |
| 09/29/2004 | EP1461359A2 Novel anti-igf-ir antibodies and uses thereof |
| 09/29/2004 | EP1461358A1 Ifnar2 muteins, their production and use |
| 09/29/2004 | EP1461340A2 Trioxane derivatives as antimalaria or anticancer compounds |
| 09/29/2004 | EP1461336A2 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 09/29/2004 | EP1461334A2 Pyrazole derived kinase inhibitors |
| 09/29/2004 | EP1461321A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 09/29/2004 | EP1461165A1 Metallic structures incorporating bioactive materials and methods for creating the same |
| 09/29/2004 | EP1461122A2 Treatment of genitourinary tract disorders |
| 09/29/2004 | EP1461093A1 Milk protein biofilm and uses thereof |
| 09/29/2004 | EP1461092A1 Process for coating a surface of a stent |
| 09/29/2004 | EP1461091A2 Composition and method for decreasing upper respiratory airway resistance |
| 09/29/2004 | EP1461090A2 Composition and method for treatment of otitis media |
| 09/29/2004 | EP1461083A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 09/29/2004 | EP1461076A2 Methods and compositions for treating lesions of the respiratory epithelium |
| 09/29/2004 | EP1461071A1 Muscle transcription factors |
| 09/29/2004 | EP1461070A2 Combined use of a glp-1 compound and a modulator of diabetic late complications |
| 09/29/2004 | EP1461069A2 Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| 09/29/2004 | EP1461063A2 Treatment of glioblastoma with thymosin-alpha 1 |
| 09/29/2004 | EP1461062A2 Composition and method for treating chronic allograft rejection |
| 09/29/2004 | EP1461055A1 Anti-bacterial plant compositions |
| 09/29/2004 | EP1461045A2 Glucosamine organic acid adducts |
| 09/29/2004 | EP1461043A1 Oral pharmaceutical products containing 17 beta-estradiol-3 lower alkanoate, method of administering the same and process of preparation |
| 09/29/2004 | EP1461039A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 09/29/2004 | EP1461033A2 Methods and compositions for ameliorating the undesirable effects of chemotherapy |
| 09/29/2004 | EP1461032A2 Use of tyrosine kinase inhibitors for promoting hair growth |
| 09/29/2004 | EP1461030A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma |
| 09/29/2004 | EP1461028A2 Treatment for age-related macular degeneration |
| 09/29/2004 | EP1461027A1 Treatment of neoplasia |
| 09/29/2004 | EP1461026A2 Method for treating ocular hypertension |
| 09/29/2004 | EP1461024A1 Treatment of wounds and compositions employed |
| 09/29/2004 | EP1461023A2 Prospective identification and characterization of breast cancer stem cells |
| 09/29/2004 | EP1461019A2 Bioadhesive drug delivery system with enhanced gastric retention |
| 09/29/2004 | EP1461018A2 Dual controlled release dosage form |
| 09/29/2004 | EP1461015A2 Compositions containing both sedative and non-sedative antihistamines |
| 09/29/2004 | EP1461014A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 09/29/2004 | EP1461001A2 Cancer-associated epitope |
| 09/29/2004 | EP1460969A2 Prevention and treatment of androgen-deprivation induced osteoporosis |
| 09/29/2004 | EP1460967A2 Composition and method for treatment of otitis externa |
| 09/29/2004 | EP1339502B1 Device for Coating an Object with an Active Ingredient and Method for Producing a Partial or Complete Active Ingredient Coating on and in Implants and Onplants as well as Use of or Product Obtained through such a Method |
| 09/29/2004 | EP1292288B1 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 09/29/2004 | EP1276493B1 Cxcr4 agonist treatment of hematopoietic cells |
| 09/29/2004 | EP1254143B1 Lipid-based drug delivery systems |
| 09/29/2004 | EP1244462B1 Pharmaceutical composition comprised of spider venoms, the production thereof, and its use for treating tumor diseases |
| 09/29/2004 | EP1239882B1 Formulations of adenosine a1 agonists and 5ht3 agonists |
| 09/29/2004 | EP1210320B1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/29/2004 | EP1202959B1 Aminobenzophenones as inhibitors of il-1-beta and tnf-alpha |
| 09/29/2004 | EP1202957B1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/29/2004 | EP1176960B1 Synergistic combination comprising roflumilast and a pde-3 inhibitor |
| 09/29/2004 | EP1169339B1 Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease |
| 09/29/2004 | EP1124563B1 Methods and compositions for the prevention of tolerance to bronchodilators |
| 09/29/2004 | EP1090116B1 Transgenic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 09/29/2004 | EP1067965B1 Pharmaceutical composition for treating cerebral apoplexy and craniocerebral trauma |
| 09/29/2004 | EP1015012A4 Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
| 09/29/2004 | EP1003526B1 Covalently linked n,o-carboxymethylchitosan and uses thereof |
| 09/29/2004 | EP0989848B1 Film-coated tablet for improved upper gastrointestinal tract safety |
| 09/29/2004 | EP0969813B1 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| 09/29/2004 | EP0914146B1 Morphogen treatment for chronic renal failure |
| 09/29/2004 | EP0804238B1 Method to prevent transplant rejection |
| 09/29/2004 | EP0797451B1 Compositions containing arabinogalactan and polyphenols from larix for treating gastrointestinal disorders |
| 09/29/2004 | EP0699079B1 Bioactive and/or targeted dendrimer conjugates comprising genetic materials |
| 09/29/2004 | CN1533390A Drugs containing triazaspiro [5,5] undecane derivatives as the active ingredient |
| 09/29/2004 | CN1533293A Combinations comprising epothilones and pharmaceutical uses thereof |
| 09/29/2004 | CN1533284A Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases |
| 09/29/2004 | CN1533283A Use of osteopontin for treatment and/or prevention of neurologic diseases |
| 09/29/2004 | CN1533273A Metronomic dosing of taxanes |
| 09/29/2004 | CN1533270A Oral administered dosage form of GABA anolog prodrugs having reduced toxicity |
| 09/29/2004 | CN1533269A Carotenoids as anti-hypertension agents |
| 09/29/2004 | CN1532292A Transcription active test |
| 09/29/2004 | CN1168451C Use of thiazolidinedione and sulphonylurea composition in preparing medicine for treating diabetes |
| 09/29/2004 | CN1168448C Medicament for preventing and/or treating a memmary carcinoma, containing a steroidal aromatase inhibitor |
| 09/29/2004 | CN1168442C Methods and compsns. for stimulating neurite growth |
| 09/29/2004 | CN1168439C Drug delivery device, especially for delivery of progestins and estrogens |
| 09/28/2004 | US6797811 Antibodies to chemokine receptor 88C |
| 09/28/2004 | US6797702 Methods and compositions comprising DNA damaging agents and P53 |
| 09/28/2004 | US6797696 Contacting a bodily fluid with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (haah) polypeptide to form a complex and detecting the complex; treating malignant neoplasms by inhibiting haah. |
| 09/28/2004 | US6797694 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction |
| 09/28/2004 | US6797692 Use of glutamate antagonists for the treatment of cancer |
| 09/28/2004 | US6797499 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof |
| 09/28/2004 | US6797289 Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 09/28/2004 | US6797284 Plant extracts and amino acids, that can be used to reduce tobacco smoke addiction |
| 09/28/2004 | US6797281 Esters of I-carnitine or alkanoyl I-carnitines |
| 09/28/2004 | US6797269 Mesenchymal stem cells as immunosuppressants |
| 09/28/2004 | US6797268 Pharmaceutical composition useful in the treatment of peptic ulcers |
| 09/28/2004 | US6797264 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 09/28/2004 | US6797263 Compositions and methods for achieving immune suppression |
| 09/28/2004 | US6797260 Bleeding control and healing aid compositions and methods of use |
| 09/28/2004 | US6797259 Delivery of muscle relaxants through an inhalation route |